Viralex, a drug consisting of Inosine Pranobex, has been approved by the Drugs Controller General of India (DCGI) as an effective and safe drug for the management of mild to moderate COVID-19 and other acute viral respiratory infections. A multi-center, double-blind, randomized, placebo-controlled clinical trial was conducted during the delta wave of COVID-19. The trial showed early improvement and complete relief from mild to moderate COVID-19 symptoms.

The drug developed by Themis Medicare has been approved by the DCGI for the treatment of influenza and other acute viral respiratory infections (AVRI), including COVID-19, mucocutaneous herpes, genital warts, and subacute sclerosing panencephalitis (SSPE).

Inosine Pranobex is an immunomodulatory and antiviral agent that bolsters the body’s defenses against viral infections by enhancing both innate and adaptive immunity. The medicine is also useful for patients with severe co-morbidities and suppressed immunity due to its dual mode of action. The drug is an oral medication (500 mg tablet) available only on a prescription from a registered medical practitioner.

(Source: https://health.economictimes.indiatimes.com/news/pharma/dcgi-approved-themis-medicares-viralex-effective-against-covid-19-viral-respiratory-infections/92727299 )